APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Avelumab

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Avelumab Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

Report ID 173968460323 December 2025175 pages

Choose your research edition.

Industry ResearchAvelumab Industry Research Report 2026105 pages · $2,950 USDIndustry Growth & TrendsGlobal Avelumab Industry Growth and Trends Forecast to 203273 pages · $3,450 USDMarket StructureGlobal Avelumab Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032175 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Avelumab Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal Avelumab Market Analysis and Forecast 2026-2032196 pages · $4,950 USD

Market perspective

The global Avelumab market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Avelumab is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Avelumab is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Avelumab is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Avelumab is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Avelumab include Merck and Pfizer among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Avelumab market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Avelumab and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Avelumab sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Avelumab market size, projected growth trends, production technologies, key applications, and end-use industries.

Avelumab Segment by Company

Merck

Pfizer

Avelumab Segment by Type

By Usage

By Specifications

Avelumab Segment by Application

Merkel-cell Carcinoma

Non-small Cell Lung Carcinoma (NSCLC)

Others

Avelumab Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Avelumab market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Avelumab and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Avelumab.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Avelumab market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Avelumab manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Avelumab in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Avelumab in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Avelumab Industry Trends Table 2. Avelumab Industry Drivers Table 3. Avelumab Industry Opportunities and Challenges Table 4. Avelumab Industry Restraints Table 5. Global Avelumab Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Avelumab Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Avelumab Sales by Manufacturers (k units) & (2021-2026) Table 8. Global Avelumab Sales Market Share by Manufacturers Table 9. Global Avelumab Average Sales Price (US$/unit) of Manufacturers (2021-2026) Table 10. Global Avelumab Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Avelumab Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Avelumab Manufacturers, Product Type & Application Table 13. Global Avelumab Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Avelumab by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Type One Table 17. Major Manufacturers of Type Two Table 18. Global Avelumab Sales by Type 2021 VS 2025 VS 2032 (k units) Table 19. Global Avelumab Sales by Type (2021-2026) & (k units) Table 20. Global Avelumab Sales by Type (2027-2032) & (k units) Table 21. Global Avelumab Sales Market Share by Type (2021-2026) Table 22. Global Avelumab Sales Market Share by Type (2027-2032) Table 23. Global Avelumab Revenue by Type 2021 VS 2025 VS 2032 (k units) Table 24. Global Avelumab Revenue by Type (2021-2026) & (k units) Table 25. Global Avelumab Revenue by Type (2027-2032) & (k units) Table 26. Global Avelumab Revenue Market Share by Type (2021-2026) Table 27. Global Avelumab Revenue Market Share by Type (2027-2032) Table 28. Major Manufacturers of Merkel-cell Carcinoma Table 29. Major Manufacturers of Non-small Cell Lung Carcinoma (NSCLC) Table 30. Major Manufacturers of Others Table 31. Global Avelumab Sales by Application 2021 VS 2025 VS 2032 (k units) Table 32. Global Avelumab Sales by Application (2021-2026) & (k units) Table 33. Global Avelumab Sales by Application (2027-2032) & (k units) Table 34. Global Avelumab Sales Market Share by Application (2021-2026) Table 35. Global Avelumab Sales Market Share by Application (2027-2032) Table 36. Global Avelumab Revenue by Application 2021 VS 2025 VS 2032 (k units) Table 37. Global Avelumab Revenue by Application (2021-2026) & (k units) Table 38. Global Avelumab Revenue by Application (2027-2032) & (k units) Table 39. Global Avelumab Revenue Market Share by Application (2021-2026) Table 40. Global Avelumab Revenue Market Share by Application (2027-2032) Table 41. Global Avelumab Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 42. Global Avelumab Sales by Region (2021-2026) & (k units) Table 43. Global Avelumab Sales Market Share by Region (2021-2026) Table 44. Global Avelumab Sales Forecasted by Region (2027-2032) & (k units) Table 45. Global Avelumab Sales Forecasted Market Share by Region (2027-2032) Table 46. North America Avelumab Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 47. North America Avelumab Sales by Country (2021-2026) & (k units) Table 48. North America Avelumab Sales by Country (2027-2032) & (k units) Table 49. Europe Avelumab Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 50. Europe Avelumab Sales by Country (2021-2026) & (k units) Table 51. Europe Avelumab Sales by Country (2027-2032) & (k units) Table 52. Asia Pacific Avelumab Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 53. Asia Pacific Avelumab Sales by Country (2021-2026) & (k units) Table 54. Asia Pacific Avelumab Sales by Country (2027-2032) & (k units) Table 55. South America, Middle East and Africa Avelumab Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 56. South America, Middle East and Africa Avelumab Sales by Country (2021-2026) & (k units) Table 57. South America, Middle East and Africa Avelumab Sales by Country (2027-2032) & (k units) Table 58. Global Avelumab Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 59. Global Avelumab Revenue by Region (2021-2026) & (US$ Million) Table 60. Global Avelumab Revenue by Region (2027-2032) & (US$ Million) Table 61. Global Avelumab Revenue Market Share by Region (2021-2026) Table 62. Global Avelumab Revenue Market Share by Region (2027-2032) Table 63. Merck Company Information Table 64. Merck Business Overview Table 65. Merck Avelumab Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 66. Merck Avelumab Product Portfolio Table 67. Merck Recent Development Table 68. Pfizer Company Information Table 69. Pfizer Business Overview Table 70. Pfizer Avelumab Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. Pfizer Avelumab Product Portfolio Table 72. Pfizer Recent Development Table 73. Key Raw Materials Table 74. Raw Materials Key Suppliers Table 75. Avelumab Distributors List Table 76. Avelumab Customers List Table 77. Research Programs/Design for This Report Table 78. Authors List of This Report Table 79. Secondary Sources Table 80. Primary Sources List of Figures Figure 1. Avelumab Product Image Figure 2. Global Avelumab Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Avelumab Market Size (2021-2032) & (US$ Million) Figure 4. Global Avelumab Sales (2021-2032) & (k units) Figure 5. Global Avelumab Average Price (US$/unit) & (2021-2032) Figure 6. Global Top 5 and 10 Avelumab Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Type I Image Figure 9. Type II Image Figure 10. Global Avelumab Sales by Type (2021 VS 2025 VS 2032) & (k units) Figure 11. Global Avelumab Sales Market Share 2021 VS 2025 VS 2032 Figure 12. Global Avelumab Sales Market Share by Type (2021-2032) Figure 13. Global Avelumab Revenue by Type (2021 VS 2025 VS 2032) & (k units) Figure 14. Global Avelumab Revenue Market Share 2021 VS 2025 VS 2032 Figure 15. Global Avelumab Revenue Market Share by Type (2021-2032) Figure 16. Merkel-cell Carcinoma Image Figure 17. Non-small Cell Lung Carcinoma (NSCLC) Image Figure 18. Others Image Figure 19. Global Avelumab Sales by Application (2021 VS 2025 VS 2032) & (k units) Figure 20. Global Avelumab Sales Market Share 2021 VS 2025 VS 2032 Figure 21. Global Avelumab Sales Market Share by Application (2021-2032) Figure 22. Global Avelumab Revenue by Application (2021 VS 2025 VS 2032) & (k units) Figure 23. Global Avelumab Revenue Market Share 2021 VS 2025 VS 2032 Figure 24. Global Avelumab Revenue Market Share by Application (2021-2032) Figure 25. North America Avelumab Sales and Growth Rate (2021-2032) & (k units) Figure 26. North America Avelumab Sales Market Share by Country (2021-2032) Figure 27. U.S. Avelumab Sales and Growth Rate (2021-2032) & (k units) Figure 28. Canada Avelumab Sales and Growth Rate (2021-2032) & (k units) Figure 29. Mexico Avelumab Sales and Growth Rate (2021-2032) & (k units) Figure 30. Europe Avelumab Sales and Growth Rate (2021-2032) & (k units) Figure 31. Europe Avelumab Sales Market Share by Country (2021-2032) Figure 32. Germany Avelumab Sales and Growth Rate (2021-2032) & (k units) Figure 33. France Avelumab Sales and Growth Rate (2021-2032) & (k units) Figure 34. U.K. Avelumab Sales and Growth Rate (2021-2032) & (k units) Figure 35. Italy Avelumab Sales and Growth Rate (2021-2032) & (k units) Figure 36. Netherlands Avelumab Sales and Growth Rate (2021-2032) & (k units) Figure 37. Asia Pacific Avelumab Sales and Growth Rate (2021-2032) & (k units) Figure 38. Asia Pacific Avelumab Sales Market Share by Country (2021-2032) Figure 39. China Avelumab Sales and Growth Rate (2021-2032) & (k units) Figure 40. Japan Avelumab Sales and Growth Rate (2021-2032) & (k units) Figure 41. South Korea Avelumab Sales and Growth Rate (2021-2032) & (k units) Figure 42. Southeast Asia Avelumab Sales and Growth Rate (2021-2032) & (k units) Figure 43. India Avelumab Sales and Growth Rate (2021-2032) & (k units) Figure 44. Australia Avelumab Sales and Growth Rate (2021-2032) & (k units) Figure 45. South America, Middle East and Africa Avelumab Sales and Growth Rate (2021-2032) & (k units) Figure 46. South America, Middle East and Africa Avelumab Sales Market Share by Country (2021-2032) Figure 47. Brazil Avelumab Sales and Growth Rate (2021-2032) & (k units) Figure 48. South Africa Avelumab Sales and Growth Rate (2021-2032) & (k units) Figure 49. Saudi Arabia Avelumab Sales and Growth Rate (2021-2032) & (k units) Figure 50. Turkey Avelumab Sales and Growth Rate (2021-2032) & (k units) Figure 51. Argentina Avelumab Sales and Growth Rate (2021-2032) & (k units) Figure 52. UAE Avelumab Sales and Growth Rate (2021-2032) & (k units) Figure 53. Egypt Avelumab Sales and Growth Rate (2021-2032) & (k units) Figure 54. Chile Avelumab Sales and Growth Rate (2021-2032) & (k units) Figure 55. Global Avelumab Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Global Avelumab Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 57. North America Avelumab Revenue (2021-2032) & (US$ Million) Figure 58. North America Avelumab Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 59. Europe Avelumab Revenue (2021-2032) & (US$ Million) Figure 60. Europe Avelumab Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 61. Asia-Pacific Avelumab Revenue (2021-2032) & (US$ Million) Figure 62. Asia-Pacific Avelumab Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. South America, Middle East and Africa Avelumab Revenue (2021-2032) & (US$ Million) Figure 64. South America, Middle East and Africa Avelumab Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. Avelumab Value Chain Figure 66. Manufacturing Cost Structure Figure 67. Avelumab Production Mode & Process Figure 68. Direct Comparison with Distribution Share Figure 69. Distributors Profiles Figure 70. Years Considered Figure 71. Research Process Figure 72. Key Executives Interviewed

Scope & coverage.

Applications
  • Merkel-cell Carcinoma
  • Non-small Cell Lung Carcinoma (NSCLC)
  • Others
Companies covered
  • Merck
  • Pfizer

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Avelumab Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Avelumab Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Avelumab Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Avelumab Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Avelumab Market Dynamics
  1. 2.1 Avelumab Industry Trends
  2. 2.2 Avelumab Industry Drivers
  3. 2.3 Avelumab Industry Opportunities and Challenges
  4. 2.4 Avelumab Industry Restraints
3 Avelumab Market by Manufacturers
  1. 3.1 Global Avelumab Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Avelumab Sales by Manufacturers (2021-2026)
  3. 3.3 Global Avelumab Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Avelumab Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Avelumab Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Avelumab Manufacturers, Product Type & Application
  7. 3.7 Global Avelumab Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Avelumab Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Avelumab Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Avelumab Tier 1, Tier 2, and Tier 3
4 Avelumab Market by Type
  1. 4.1 Avelumab Type Introduction
  2. 4.1.1 By Usage
  3. 4.1.2 By Specifications
  4. 4.2 Global Avelumab Sales by Type
  5. 4.2.1 Global Avelumab Sales by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Avelumab Sales by Type (2021-2032)
  7. 4.2.3 Global Avelumab Sales Market Share by Type (2021-2032)
  8. 4.3 Global Avelumab Revenue by Type
  9. 4.3.1 Global Avelumab Revenue by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Avelumab Revenue by Type (2021-2032)
  11. 4.3.3 Global Avelumab Revenue Market Share by Type (2021-2032)
5 Avelumab Market by Application
  1. 5.1 Avelumab Application Introduction
  2. 5.1.1 Merkel-cell Carcinoma
  3. 5.1.2 Non-small Cell Lung Carcinoma (NSCLC)
  4. 5.1.3 Others
  5. 5.2 Global Avelumab Sales by Application
  6. 5.2.1 Global Avelumab Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Avelumab Sales by Application (2021-2032)
  8. 5.2.3 Global Avelumab Sales Market Share by Application (2021-2032)
  9. 5.3 Global Avelumab Revenue by Application
  10. 5.3.1 Global Avelumab Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Avelumab Revenue by Application (2021-2032)
  12. 5.3.3 Global Avelumab Revenue Market Share by Application (2021-2032)
6 Global Avelumab Sales by Region
  1. 6.1 Global Avelumab Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Avelumab Sales by Region (2021-2032)
  3. 6.2.1 Global Avelumab Sales by Region (2021-2026)
  4. 6.2.2 Global Avelumab Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Avelumab Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Avelumab Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Avelumab Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Avelumab Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Avelumab Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Avelumab Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Avelumab Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Avelumab Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Avelumab Revenue by Region
  1. 7.1 Global Avelumab Revenue by Region
  2. 7.1.1 Global Avelumab Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Avelumab Revenue by Region (2021-2026)
  4. 7.1.3 Global Avelumab Revenue by Region (2027-2032)
  5. 7.1.4 Global Avelumab Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Avelumab Revenue (2021-2032)
  8. 7.2.2 North America Avelumab Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Avelumab Revenue (2021-2032)
  11. 7.3.2 Europe Avelumab Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Avelumab Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Avelumab Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Avelumab Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Avelumab Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Merck
  2. 8.1.1 Merck Company Information
  3. 8.1.2 Merck Business Overview
  4. 8.1.3 Merck Avelumab Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Merck Avelumab Product Portfolio
  6. 8.1.5 Merck Recent Developments
  7. 8.2 Pfizer
  8. 8.2.1 Pfizer Company Information
  9. 8.2.2 Pfizer Business Overview
  10. 8.2.3 Pfizer Avelumab Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Pfizer Avelumab Product Portfolio
  12. 8.2.5 Pfizer Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Avelumab Value Chain Analysis
  2. 9.1.1 Avelumab Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Avelumab Production Mode & Process
  6. 9.2 Avelumab Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Avelumab Distributors
  9. 9.2.3 Avelumab Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst